Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Instituto do Cancer do Estado de São Paulo
University Hospital Tuebingen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
West China Hospital
West China Hospital
National Institutes of Health Clinical Center (CC)
Fudan University
University College Cork
Rutgers, The State University of New Jersey
Rutgers, The State University of New Jersey
Sun Yat-sen University
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University Health Network, Toronto
Mayo Clinic
The Netherlands Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Fudan University
Jonsson Comprehensive Cancer Center
Hospital Israelita Albert Einstein
UNICANCER
MedSIR
German Cancer Research Center
University College, London
Sun Yat-sen University
Institute of Cancer Research, United Kingdom
UNICANCER
Fudan University
Shanghai Bovax Biotechnology Co., Ltd.
The Netherlands Cancer Institute
University of Maryland, College Park
The Affiliated Hospital of Qingdao University
SCG Cell Therapy Pte. Ltd.
M.D. Anderson Cancer Center
Gene Surgery LLC
University Medical Center Groningen
Shanghai Bovax Biotechnology Co., Ltd.
University of Maryland, College Park
Latin American Cooperative Oncology Group
UNICANCER
University of Southampton
HRYZ Biotech Co.
HRYZ Biotech Co.
Deciphera Pharmaceuticals, LLC
Dana-Farber Cancer Institute
The Netherlands Cancer Institute
The Affiliated Hospital of Qingdao University